Anticataract activity of Kohl-Chikni Dawa—a compound ophthalmic formulation of Unani medicine in alloxan-diabetic rats

• Published in: Journal of ethnopharmacology 2003-05, Vol.86 (1), p.109-112
• Main Authors: Siddiqui, T.A, Shadab, Z, Nishat, I, Ayasha, N, Zehra, Z, Alavi, S.H
• Format: Article
• Language: English
• Subjects: Alloxan-diabetic rats; Animals; Anticataract activity; Associated diseases and complications; Biological and medical sciences; Blood Glucose - drug effects; Blood sugar; Cataract - etiology; Cataract - prevention & control; Diabetes Mellitus, Experimental - complications; Diabetes. Impaired glucose tolerance; Dose-Response Relationship, Drug; Endocrine pancreas. Apud cells (diseases); Endocrinopathies; Female; General pharmacology; Kohl-Chikni Dawa; Medical sciences; Medicine, Unani; Ophthalmic Solutions - chemical synthesis; Ophthalmic Solutions - therapeutic use; Pharmacognosy. Homeopathy. Health food; Pharmacology. Drug treatments; Rats
• ISSN: 0378-8741; 1872-7573
• DOI: 10.1016/S0378-8741(03)00046-1

Kohl-Chikni Dawa ( KCD), a compound ophthalmic formulation of Unani medicine was studied for anticataract activity in alloxan-diabetic rats. When one drop of 3% KCD solution was applied (once and twice daily) in both eyes for 90 days in alloxan-diabetic rats, a significant reduction of lens opacification was noticed. On the other hand, local application of 3% KCD solution (once and twice daily) did not reduce the blood sugar concentration in normal and alloxan-diabetic rats. Blood sugar in all the rats was estimated by glucometer and the morphological changes of the lenses were examined by slit-lamp biomicroscope before and after therapy at various time intervals for 90 days. These results suggest that the local application of 3% KCD solution possesses anticataract effect in alloxan-induced hyperglycaemic rats.